A clinical Response in Metastatic Castration-resistant Prostate Cancer
(mCRPC) Cases Treated with Supra-physiological Doses of Testosterone:
Bipolar Androgen Therapy
- Senji Hoshi,
- Vladimir Bilim
, - Kiyotsugu Hoshi,
- Takuya Nakagawa,
- Sadanobu Sato,
- Rie Sakagami,
- Masato Konno,
- Takashi Kudo,
- Kenji Numahata,
- Isoji Sasagawa
Abstract
Androgen deprivation therapy is a standard of care for metastatic
prostate cancer, however, eventually, all men relapse. A paradoxical
approach utilizing high doses of testosterone in castration-resistant
prostate cancer patients demonstrated clinical responses. Here we report
on four heavily pretreated CRPC patients successfully treated with
supra-physiological doses of testosterone.27 Aug 2021Submitted to Clinical Case Reports 27 Aug 2021Submission Checks Completed
27 Aug 2021Assigned to Editor
11 Sep 2021Reviewer(s) Assigned
25 Dec 2021Review(s) Completed, Editorial Evaluation Pending
25 Dec 2021Editorial Decision: Revise Minor
29 Jan 20221st Revision Received
31 Jan 2022Submission Checks Completed
31 Jan 2022Assigned to Editor
31 Jan 2022Review(s) Completed, Editorial Evaluation Pending
31 Jan 2022Editorial Decision: Accept
